AUSTIN, Texas,
June 20, 2017
/PRNewswire/ -- Savara Inc. (NASDAQ: SVRA), a
clinical-stage specialty pharmaceutical company focused on the
development and commercialization of novel therapies for the
treatment of serious or life-threatening rare respiratory diseases,
today announced that the Company will join the Russell
Microcap® Index at the
conclusion of the Russell indexes annual reconstitution, effective
at U.S. market open on June 26, 2017.
Membership in the Russell Microcap® Index, which remains
in place for one year, provides automatic inclusion in the
appropriate growth and value style indexes. FTSE Russell determines
membership for its Russell indexes primarily by objective
market-capitalization rankings and style attributes.
"Savara's inclusion in the Russell
Microcap® Index is a notable
milestone for us, and we believe it reflects the progress we have
made in building a leading orphan lung disease company," stated
Rob Neville, Chief Executive Officer
of Savara. "The Russell indexes are widely followed in the
investment community and we believe our inclusion in the Russell
Microcap® Index will
contribute to expanding awareness of Savara among institutional
investors and contribute to an increase in the trading volume in
our shares."
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $8.4 trillion in assets are benchmarked against
Russell's US indexes. Russell indexes are part of FTSE Russell, a
leading global index provider. For more information on the Russell
Microcap® Index and the Russell indexes reconstitution,
go to the "Russell Reconstitution" section on the FTSE
Russell website.
About Savara
Savara Inc. is a
clinical-stage specialty pharmaceutical company focused on the
development and commercialization of novel therapies for the
treatment of serious or life-threatening rare respiratory diseases.
Savara's pipeline comprises Molgradex, a Phase 3 stage inhaled
granulocyte-macrophage colony-stimulating factor, or GM-CSF,
AeroVanc, an inhaled vancomycin in preparation for Phase 3, and
Aironite, an inhaled sodium nitrite in Phase 2 development.
Savara's strategy involves expanding its pipeline of potentially
best-in-class products through indication expansion, strategic
development partnerships and product acquisitions, with the goal of
becoming a leading company in its field. Savara's management team
has significant experience in orphan drug development and pulmonary
medicine, in identifying unmet needs, creating and acquiring new
product candidates, and effectively advancing them to approvals and
commercialization. More information can be found
at www.savarapharma.com. (Twitter:
@SavaraPharma)
About FTSE Russell
FTSE Russell is
a leading global index provider creating and managing a wide range
of indexes, data and analytic solutions to meet client needs across
asset classes, style and strategies. Covering 98% of the investable
market, FTSE Russell indexes offer a true picture of global
markets, combined with the specialist knowledge gained from
developing local benchmarks around the world. FTSE Russell index
expertise and products are used extensively by institutional and
retail investors globally. Approximately $12.5 trillion is currently benchmarked to FTSE
Russell indexes.
For over 30 years, leading asset owners, asset managers,
ETF providers and investment banks have chosen FTSE Russell indexes
to benchmark their investment performance and create investment
funds, ETFs, structured products and index-based derivatives. FTSE
Russell indexes also provide clients with tools for asset
allocation, investment strategy analysis and risk management. A
core set of universal principles guides FTSE Russell index design
and management: a transparent rules-based methodology is informed
by independent committees of leading market participants. FTSE
Russell is focused on index innovation and customer partnership
applying the highest industry standards and embracing the IOSCO
Principles. FTSE Russell is wholly owned by London Stock Exchange
Group. For more information, visit
www.ftserussell.com
Forward Looking Statements
Savara cautions you that statements in this
press release that are not a description of historical fact are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words referencing future
events or circumstances such as "expect," "intend," "plan,"
"anticipate," "believe," and "will," among others. Such statements
include, but are not limited to, statements relating to our belief
that inclusion in the index reflects the progress we
have made in building a leading orphan lung disease company, that
our inclusion in the index will contribute to expanding awareness
of Savara among institutional investors and increase the trading
volume in our shares. Savara may not actually achieve
any of the matters referred to in such forward looking statements,
and you should not place undue reliance on these forward-looking
statements. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. These
forward-looking statements are based upon Savara's current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, our ability to
execute on our business plan, the actual awareness of Savara and
our business and other factors that could impact the trading volume
in our shares. All forward-looking statements are expressly
qualified in their entirety by these cautionary statements. For a
detailed description of our risks and uncertainties, you are
encouraged to review our documents filed with the SEC including our
recent filings on Form 8-K, 10-Q and 10-K. You are cautioned not to
place undue reliance on forward-looking statements, which speak
only as of the date on which they were made. Savara undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were made,
except as may be required by law.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/savara-set-to-join-russell-microcap-index-300476348.html
SOURCE Savara Inc.